Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: A systematic review

JAMA

Volumn 297, Issue 23, 2007, Pages 2603-2616

  Ter Kuile, Feiko O ^a,b   Van Eijk, Annemieke M ^c   Filler, Scott J ^b  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; FANSIDAR; HEMOGLOBIN; PLACEBO; ANTIMALARIAL AGENT; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE; UNCLASSIFIED DRUG;

ANEMIA; BED NET; BIBLIOGRAPHIC DATABASE; CASE MANAGEMENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA ANALYSIS; DATA EXTRACTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EMBASE; HEMOGLOBIN BLOOD LEVEL; HIGH BIRTH WEIGHT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LOW BIRTH WEIGHT; MALARIA; MALARIA CONTROL; MEDLINE; PARASITEMIA; PLACENTA; PRIMIGRAVIDA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SKIN MANIFESTATION; TREATMENT FAILURE; DRUG COMBINATION; DRUG RESISTANCE; FEMALE; PREGNANCY; PREGNANCY COMPLICATION;

ANTIMALARIALS; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PYRIMETHAMINE; SULFADOXINE;

EID: 34250682548     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.23.2603     Document Type: Review

References (47)

1. World Health Organization Regional Office for Africa. A Strategic Framework for Malaria Prevention and Control During Pregnancy in the African Region. Brazzaville, Congo: World Health Organization Regional Office for Africa; 2004.
2. White NJ. Intermittent presumptive treatment for malaria. PLoS Med. 2005;2:e3.
3. World Health Organization. Susceptibility of Plasmodium falciparum to Antimalarial Drugs: Report on Global Monitoring 1996-2004. Geneva, Switzerland: World Health Organization; 2005.
4. World Health Organization Regional Office for Africa. Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated Falciparum Malaria in Areas With Intense Transmission. Brazzaville, Congo: World Health Organization Regional Office for Africa; 1996.
5. World Health Organization. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Geneva, Switzerland: World Health Organization; 2003.
6. Kalanda GC, Hill J, Verhoeff FH, Brabin BJ. Comparative efficacy of chloroquine and sulfadoxine-pyrimethamine in pregnant women and children: a meta-analysis. Trop Med Int Health. 2006;11:569-577.
7. Menéndez C, D'Alessandro U, ter Kuile FO. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis. 2007;7:126-135.
8. Update Software Web site. Malaria in pregnancy library [March 2007]. http://www.update-software.com/publications/malaria/. Accessed March 23, 2007.
9. The Cochrane Library. Optimal search strategy for RCTs: Appendix C. In: Cochrane Reviewers' Handbook 4.2.0. Chichester, England: John Wiley & Sons Ltd; 2003.
10. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001;323:42-46.
11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557-560.
13. Deeks JJ, Higgins JPT, Altman DG. Analysing and presenting results. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester, England: John Wiley & Sons Ltd; 2005.
14. ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg. 2004;71 (suppl):41-54.
15. Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, Wirima JJ. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg. 1994;51:515-522.
16. Nwanyanwu OC, Ziba C, Kazembe P, et al. Efficacy of sulphadoxine/ pyrimethamine for Plasmodium falciparum malaria in Malawian children under five years of age. Trop Med Int Health. 1996;1:231-235.
17. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine- pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998;59:813-822.
18. van Eijk AM, Ayisi JG, Slutsker L, et al. Effect of haematinic supplementation and malaria prevention on maternal anaemia and malaria in western Kenya. Trop Med Int Health. 2007;12:342-352.
19. van Dillen J, Custers M, Wensink A, et al. A comparison of amodiaquine and sulfadoxine-pyrimethamine as first-line treatment of falciparum malaria in Kenya. Trans R Soc Trop Med Hyg. 1999;93:185-188.
20. Omar SA, Bakari A, Owiti A, Adagu IS, Warhurst DC. Co-trimoxazole compared with sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in Kenyan children. Trans R Soc Trop Med Hyg. 2001;95:657-660.
21. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine- pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet. 1999;353: 632-636.
22. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9-17.
23. Amukoye E, Winstanley PA, Watkins WM, et al. Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother. 1997;41:2261-2264.
24. Njagi JK. The Effects of Sulfadoxine-Pyrimethamine Intermittent Treatment and Pyrethroid Impregnated Bed Netson Malaria Morbidity in Pregnancy and Birth Weight in Bondo District, Kenya [dissertation]. Nairobi, Kenya, and Copenhagen, Denmark: University of Nairobi and Danish Bilharziasis Laboratory; 2002.
25. Njagi JK, Magnussen P, Estambale B, Ouma J, Mugo B. Prevention of anaemia in pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malarious area of Kenya: a randomized controlled trial. Trans R Soc Trop Med Hyg. 2003;97:277-282.
26. Obonyo CO, Ochieng F, Taylor WR, et al. Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial. Trans R Soc Trop Med Hyg. 2003;97:585-591.
27. Challis K, Osman NB, Cotiro M, Nordahl G, Dgedge M, Bergstrom S. Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern Mozambique. Trop Med Int Health. 2004;9:1066-1073.
28. Abacassamo F, Enosse S, Aponte JJ, et al. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health. 2004;9:200-208.
29. Kayentao K, Kodio M, Newman RD, et al. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J Infect Dis. 2005;191:109-116.
30. Mbaye A, Richardson K, Balajo B, et al. A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae. Trop Med Int Health. 2006;11:992-1002.
31. Dunyo S, Ord R, Hallett R, et al. Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS Clin Trials. 2006;1:e14.
32. Filler SJ, Kazembe P, Thigpen M, et al. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J Infect Dis. 2006;194:286-293.
33. Plowe CV, Kublin JG, Dzinjalamala FK, et al. Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. BMJ. 2004;328:545.
34. National Malaria Control Center/Central Board of Health. Preliminary Findings of in Vivo Antimalarial Drug Efficacy Studies in Zambia. Lusaka, Zambia: National Malaria Control Center, Central Board of Health; 2002.
35. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1996;276:637-639.
36. Plowe CV, Doumbo OK, Djimde A, et al. Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. Am J Trop Med Hyg. 2001; 64:242-246.
37. Bloland PB, Kazembe PN, Oloo AJ, Himonga B, Barat LM, Ruebush TK. Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa. Trop Med Int Health. 1998;3:543-552.
38. Meshnick SR, Mwapasa V, Rogerson SJ. Protecting pregnant women from malaria in areas of high HIV infection prevalence. J Infect Dis. 2006;194:273-275.
39. Worrall E, Morel C, Yeung S, et al. The economics of malaria in pregnancy-a review of the evidence and research priorities. Lancet Infect Dis. 2007;7:156-168.
40. Global Fund Web site. Fighting malaria. http: //www.theglobalfund.org/en/ about/malaria/. Accessed March 23, 2007.
41. US Agency for International Development. President's malaria initiative. http://www.usaid.gov/press /factsheets/2006/fs060608.html. Accessed March 23, 2007.
42. World Bank. Rolling Bank Malaria: The World Bank Global Strategy and Booster Program. Washington, DC: International Bank for Reconstruction and Development; 2005.
43. World Health Organization. Recommendations on the use of sulfadoxine-pyrimethamine for intermittent preventive treatment during pregnancy in areas of moderate to high resistance to sulfadoxine-pyrimethamine in the African region [October 2005]. http://afro.who.int/malaria/publications/ who_sp_statement.pdf. Accessibility verified May 23, 2007.
44. Hastings MD, Bates SJ, Blackstone EA, Monks SM, Mutabingwa TK, Sibley CH. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Trans R Soc Trop Med Hyg. 2002;96:674-676.
45. Alker AP, Mwapasa V, Purfield A, et al. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob Agents Chemother. 2005;49:3919-3921.
46. Färnert A, Tengstam K, Palme IB, et al. Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis. Am J Trop Med Hyg. 2002;66:487-491.
47. Staedke SG, Sendagire H, Lamola S, Kamya MR, Dorsey G, Rosenthal PJ. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health. 2004;9:624-629.